Further Study supports use of Nevisense within new Non-melanoma Skin Cancer application

These results support a new clinical application that is an important part of our growth strategy. We continue to leverage our technology platform to both add clinical value and expand the market segments we address. We believe that the Non-melanoma Skin Cancer application will help us achieve both goals, and short term be key in accelerating our growth in Germany. We look forward to releasing the application as soon as our Medical Device Regulation approval is complete, which we expect around the end of the first quarter", says Simon Grant, CEO of SciBase.

These results support a new clinical application that is an important part of our growth strategy. We continue to leverage our technology platform to both add clinical value and expand the market segments we address. We believe that the Non-melanoma Skin Cancer application will help us achieve both goals, and short term be key in accelerating our growth in Germany. We look forward to releasing the application as soon as our Medical Device Regulation approval is complete, which we expect around the end of the first quarter", says Simon Grant, CEO of SciBase.

For more information please contact:

Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: [email protected] 

Certified Advisor:

Avanza
Tel: +46 8 409 421 20
Email: [email protected] 

About SciBase and Nevisense

SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/further-study-supports-use-of-nevisense-within-new-non-melanoma-skin-cancer-application,c3280337

The following files are available for download: